Biography:
Chang Yi Wang is the Chairperson and CSO of United Biomedical Asia (UBI Asia), a member of the UBI group of companies she founded dedicated to the discovery, development, and commercialization of immunotherapeutic vaccines and monoclonal antibodies for infectious diseases and neurodegenerative disorders. She was the first Asian woman accepted into Rockefeller University’s Ph.D. program back in 1973, where she received training from and worked with Nobel Laureate professors. Dr. Wang dedicates to the use of designer peptides and proteins as the tool for application in diagnostics, vaccines, and immunotherapeutics. Dr. Wang has published 140 peer- reviewed scientific papers.
Title : Bridging the Gaps: The Urgency for a Pan-SARS-CoV-2 Vaccine and the Potential of T Cell Immunity-promoting UB-612 Vaccine that targets both Spike and non-Spike proteins